BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34855886)

  • 1. Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    Bruckmann NM; Kirchner J; Morawitz J; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Ingenwerth M; Schaarschmidt BM; Li Y; Stang A; Antoch G; Sawicki LM; Buchbender C
    PLoS One; 2021; 16(12):e0260804. PubMed ID: 34855886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of whole-body MRI and
    Bruckmann NM; Sawicki LM; Kirchner J; Martin O; Umutlu L; Herrmann K; Fendler W; Bittner AK; Hoffmann O; Mohrmann S; Dietzel F; Ingenwerth M; Schaarschmidt BM; Li Y; Kowall B; Stang A; Antoch G; Buchbender C
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2816-2825. PubMed ID: 32333068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients.
    Bruckmann NM; Kirchner J; Umutlu L; Fendler WP; Seifert R; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Antke C; Schimmöller L; Ingenwerth M; Breuckmann K; Stang A; Buchbender C; Antoch G; Sawicki LM
    Eur Radiol; 2021 Nov; 31(11):8714-8724. PubMed ID: 33912991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nodal staging between CT, MRI, and [
    Morawitz J; Bruckmann NM; Dietzel F; Ullrich T; Bittner AK; Hoffmann O; Ruckhäberle E; Mohrmann S; Häberle L; Ingenwerth M; Abrar DB; Sawicki LM; Breuckmann K; Fendler WP; Herrmann K; Buchbender C; Antoch G; Umutlu L; Kirchner J
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):992-1001. PubMed ID: 34476552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    Zhang C; Liang Z; Liu W; Zeng X; Mo Y
    BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of
    Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
    Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
    Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
    Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.
    An YS; Lee DH; Yoon JK; Lee SJ; Kim TH; Kang DK; Kim KS; Jung YS; Yim H
    Nuklearmedizin; 2014; 53(3):89-94. PubMed ID: 24220324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer.
    Ozis SE; Soydal C; Akyol C; Can N; Kucuk ON; Yagcı C; Erkek AB; Kuzu MA
    World J Surg Oncol; 2014 Feb; 12():26. PubMed ID: 24484935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.